Orkambi combines Kalydeco, also known as ivacaftor, with another compound called lumacaftor, and is designed to treat patients ages 12 and older who have two copies of the F508del genetic mutation.

    [td_text_with_title custom_title=”Latest post”]

    FDA approves Orkampi for Cystic Fybrosis

    Orkampi was approved thursday 2nd July 2015 by the FDA. Approval in europe is still pending. The drug costs 259.000 dollars given a sigh of relief to investors, sending Vertex Pharmaceuticals up in thursday and friday session. Well done.